CREABILIS THERAPEUTICS AND BIONUCLEON ENTER COLLABORATION AGREEMENT. - Colleretto Giacosa, Bioindustry Park Canavese, Italy - CREABILIS therapeutics SpA and Bionucleon Srl, today announced a collaboration agreement to co-develop new aptamer-based compounds against targets involved in inflammatory and autoimmune diseases. S. Traversa, CREABILIS therapeutics’ Chief Scientific Officer, said: “This collaboration represents an important additional strengthening of the ongoing projects of CREABILIS in the research of new therapeutical agents against targets involved in inflammation.” R. Sapio, Administrator and co-founder of Bionucleon, commented: “We are very pleased to collaborate with CREABILIS therapeutics.
International Press Release Publishing for free in 15 languages across 22 countries
Press Releases
Google-Suche:
 

Blog blogger.com

You are not logged in, so we don't know your blog. Please fill in the data to access your blog at blogger.com. The entered information will be stored for this session.
Username
Password
Blog-URL
 
Title of your post
Text of your post
 
 
Pressreleases by authors
A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z